Update information

Minor changes since publication

June 2024 Contact details for the patient access scheme for colistimethate sodium DPI (Colobreathe) updated because Essential Pharma now has responsibility for Colobreathe. Contact details for the patient access scheme for tobramycin (Colobreathe) updated because Viatris now has responsibility for tobramycin.

January 2019: Contact details for the patient access scheme for colistimethate sodium DPI (Colobreathe) updated because Colobreathe is now owned by Teva UK.

June 2013: Implementation note deleted from the start of section 1 because colistimethate sodium dry powder for inhalation is now available in the UK.

ISBN: 978-1-4731-3288-7